MELOGLIPTIN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H21FN6O
Molecular Weight	320.3652
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

F[C@H]1C[C@@H](C#N)N(C1)C(=O)CN[C@@H]2CC[C@H](CN3C=NC=N3)C2

InChI

InChIKey=JSYGLDMGERSRPC-FQUUOJAGSA-N

InChI=1S/C15H21FN6O/c16-12-4-14(5-17)22(8-12)15(23)6-19-13-2-1-11(3-13)7-21-10-18-9-20-21/h9-14,19H,1-4,6-8H2/t11-,12-,13+,14-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://newdrugapprovals.org/2015/12/11/melogliptin/ | https://adisinsight.springer.com/drugs/800021640 | https://www.biocompare.com/Life-Science-News/48978-Glenmark-s-Novel-Molecule-for-Diabetes-Melogliptin-to-Enter-Phase-III-Trials/

Melogliptin (EMD 675992 or GRC 8200) is an orally bioavailable dipeptidyl peptidase IV (DPP IV) inhibitor. Melogliptin was undergoing phase II clinical trials at Glenmark Pharmaceuticals and Merck KGaA for the treatment of type 2 diabetes. The completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes melogliptin improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dipeptidyl peptidase 4 8 Target ID: P27487 Gene ID: 1803.0 Gene Symbol: DPP4 Target Organism: Homo sapiens (Human) Sources: https://newdrugapprovals.org/2015/12/11/melogliptin/	Inhibitor 8504		1.61 nM [IC50]

Patents

Name

Type

Language

MELOGLIPTIN

Official Name

English

Melogliptin [WHO-DD]

Preferred Name

English

melogliptin [INN]

Common Name

English

(2S,4S)-4-FLUORO-1-(2-(((1R,3S)-3-((1H-1,2,4-TRIAZOL-1-YL)METHYL)CYCLOPENTYL)AMINO)ACETYL)PYRROLIDINE-2-CARBONITRILE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98086